Effects of a lactobacillus reuteri br11 mutant deficient in the cystine-transport system in a rat model of inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 57, Issue 3, 2012, Pages 713-719

  Atkins, Haydn L ^a   Geier, Mark S ^a,b   Prisciandaro, Luca D ^a,c   Pattanaik, Ashok K ^d   Forder, Rebecca E A ^a   Turner, Mark S ^e   Howarth, Gordon S ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SOUTH AUSTRALIAN RESEARCH AND DEVELOPMENT INSTITUTE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Colon; Dextran sulfate sodium; Inflammatory bowel disease; Lactobacillus reuteri; Probiotic; Ulcerative colitis

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; CYSTINE; DEXTRAN SULFATE; DRINKING WATER; PNG 201; UNCLASSIFIED DRUG; MUCIN; PROBIOTIC AGENT;

AMINO ACID TRANSPORT; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM MUTANT; COLITIS; CONTROLLED STUDY; CRYPT CELL; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX; DISEASE EXACERBATION; DISEASE MODEL; DISEASE SEVERITY; DRUG METABOLISM; ENTERITIS; FEEDING; HISTOPATHOLOGY; LACTOBACILLUS REUTERI; LACTOBACILLUS REUTERI BR11; MALE; MILK; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; COLON; GENETICS; METABOLISM; ORGAN SIZE; PATHOLOGY; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; COLON; CYSTINE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; LACTOBACILLUS REUTERI; MALE; MUCINS; ORGAN SIZE; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84859494236     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1943-0     Document Type: Article

References (35)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006; 12:S3-S9. (Pubitemid 43068428)
2. Amit-Romach E, Uni Z, Reifen R. Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis. Dis Colon Rectum. 2008;51:1828-1836.
3. Shanahan F. Probiotics in inflammatory bowel disease: therapeutic rationale and role. Adv Drug Deliv Rev. 2004;56:809-818. (Pubitemid 38520101)
4. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic escherichia coli strain nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive e-coli strains isolated from patients with crohn's disease. Aliment Pharmacol Ther. 2003;18:45-56. (Pubitemid 36897980)
5. Chapman TM, Plosker GL, Figgitt DP. Vsl #3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs. 2006;66:1371-1387. (Pubitemid 44250756)
6. Peran L, Sierra S, Comalada M, et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr. 2007;97:96-103. (Pubitemid 46662063)
7. Seksik P, Dray X, Sokol H, Marteau P. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel diseasě Mol Nutr Food Res. 2008;52: 906-912.
8. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflam Bowel Dis. 2008;14:1585-1596.
9. Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol. 2007; 115:1-11. (Pubitemid 46349312)
10. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci. 2004;107:331-341. (Pubitemid 39389300)
11. Rioux KP, Madsen KL, Fedorak RN. The role of enteric microflora in inflammatory bowel disease: human, animal studies with probiotics, prebiotics. Gastroenterol Clin N Am. 2005;34: 465-482. (Pubitemid 41097278)
12. Amit-Romach E, Uni Z, Reifen R. Mulistep mechanism of probiotic bacterium, the effect on innate immune system. Mol Nutr Food Res. 2010;54:277-284.
13. Turner MS, Woodberry T, Hafner LM, Gliffard PM. The bspA locus of Lactobacillus fermentum BR11 encodes an L-cystine uptake system. J Bacteriol. 1999;181:2192-2198. (Pubitemid 29164974)
14. Geier MS, Butler RN, Giffard PM, Howarth GS. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (dss) in rats. Int J Food Microbiol. 2007;114:267-274. (Pubitemid 46283086)
15. Lo R, Turner MS, Barry DG, Sreekumar R, Walsh TP, Gliffard PM. Cystathionine gamma-lyase is a component of cystinemediated oxidative defense in Lactobacillus reuteri BR11. J Bacteriol. 2009;191:1827-1837.
16. Turner MS, Timms P, Hafner LM, Gliffard PM. Identification and characterization of a basic cell surface-located protein from Lactobacillus fermentum BR11. J Bacteriol. 1997;179: 3310-3316. (Pubitemid 27203008)
17. Javed S, Howard A, Hirst B. Protection of intestinal cells against reactive oxygen species (ros) by amino acids. Mutagenesis. 2009;24:38.
18. Damiani CR, Benetton CAF, Stoffel C, et al. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol. 2007;22:1846-1851. (Pubitemid 47527120)
19. Sengul N, Isik S, Aslim B, Ucar G, Demirbag AE. The effect of exopolysaccharide-producing probiotic strains on gut oxidative damage in experimental colitis. Dig Dis Sci. 2011;56:707-714.
20. Hung J, Turner MS, Walsh T, Giffard PM. Bspa (CyuC) in Lactobacillus reuteri BR11 is a highly expressed high-affinity L-cystine-binding protein. Curr Microbiol. 2005;50:33-37. (Pubitemid 40655426)
21. Hung J, Cooper D, Turner MS, Walsh T, Giffard PM. Cystine uptake prevents production of hydrogen peroxide by Lactobacillus fermentum BR11. FEMS Microbiol Lett. 2003;227:93-99. (Pubitemid 41123326)
22. Rush CM, Hafner LM, Timms P. Genetic-modification of a vaginal strain of lactobacillus fermentum and its maintenance within the reproductive-tract after intravaginal administration. J Med Microbiol. 1994;41:272-278. (Pubitemid 24333794)
23. Tomas FM, Knowles SE, Owens PC, et al. Effects of full-length and truncated insulin-like growth factor-i on nitrogen-balance and muscle protein-metabolism in nitrogen-restricted rats. J Endocrinol. 1991;128:97-105.
24. Howarth GS, Xian CJ, Read LC. Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-i for 20 weeks in a rat model of chronic inflammatory bowel disease. Growth Fact. 2000;18:119-133.
25. Howarth GS, Xian CJ, Read LC. Insulin-like growth factor-1 partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol. 1998;33:180-190. (Pubitemid 28098234)
26. Gaudio E, Taddei G, Vetuschi A, et al. Dextran sulfate sodium (dss) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci. 1999;44:1458-1475. (Pubitemid 29404313)
27. Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr. 1996;126:2519-2530. (Pubitemid 26339666)
28. Longman RJ, Poulson R, Corfield AP, Warren BF, Wright NA, Thomas MG. Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J Histochem Cytochem. 2006;54:1335-1348. (Pubitemid 44788819)
29. Corfield AP, Myerscough N, Bradfield N, et al. Colonic mucins in ulcerative colitis: evidence for loss of sulfation. Glycoconj J. 1996;13:809-822. (Pubitemid 26354274)
30. Forder REA, Howarth GS, Tivey DR, Hughes RJ. Bacterial modulation of small intestinal goblet cells and mucin composition during early posthatch development of poultry. Poult Sci. 2007;86:2396-2403. (Pubitemid 350097225)
31. Yan YT, Kolachala V, Dalmasso G, et al. Temporal, spatial analysis of clinical, molecular parameters in dextran sodium sulfate induced colitis. Plos One. 2009;4:e6073.
32. Vetuschi A, Latella G, Sferra R, Caprilli R, Gaudio E. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci. 2002;47: 1447-1457. (Pubitemid 34753919)
33. Shimizu T, Suzuki M, Fujimura J, et al. The relationship between the concentration of dextran sodium sulfate and the degree of induced experimental colitis in weanling rats. J Pediatr Gastroenterol Nutr. 2003;37:481-486. (Pubitemid 39274495)
34. Mauger CA, Butler RN, Geier MS, Tooley KL, Howarth GS. Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Dig Dis Sci. 2007;52:612-619.
35. Geier MS, Butler RN, Giffard PM, Howarth GS. Prebiotic and synbiotic fructooligosaccharide administration fails to reduce the severity of experimental colitis in rats. Dis Colon Rectum. 2007;50:1061-1069. (Pubitemid 47030188)